Sunesis Shifts Focus to Flagship PDK1 Inhibitor

https://biopharmajournal.com/2020/07/06/sunesis-pharmaceuticals-inc-nasdaqsnss-reveals-plan-to-discontinue-its-vecabrutinib-program/
JOIN OUR MAILING LIST

 

 
 
 
 

IPIRA is committed to meeting the needs of people with disabilities in a timely manner by preventing and removing barriers to accessibility. We also adhere to the UC Berkeley policy on nondiscrimination, and protect the privacy of confidential information.